This company has been acquired
PRTK Aktienübersicht
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 1/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
Paratek Pharmaceuticals, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$2.23 |
| 52-Wochen-Hoch | US$3.65 |
| 52-Wochen-Tief | US$1.29 |
| Beta | 1.7 |
| 11 Monat Veränderung | 2.29% |
| 3 Monate Veränderung | 0.91% |
| 1 Jahr Veränderung | -2.62% |
| 33 Jahre Veränderung | -60.95% |
| 5 Jahre Veränderung | -77.01% |
| Veränderung seit IPO | -86.06% |
Aktuelle Nachrichten und Updates
Recent updates
Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified
Apr 17
Paratek Pharmaceuticals: Patience Is Wearing Thin
Aug 24Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M
Aug 03Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company
Jan 03The Play On Paratek Pharmaceuticals
Oct 18Peeking Back In On Paratek Pharmaceuticals
Aug 07Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial
Jun 16Paratek shares rise after FDA approves NUZYRA oral only dosing regimen
Jun 01Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business
Apr 27Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Are Analysts Optimistic?
Mar 01Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?
Feb 01Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment
Jan 04Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
Dec 01Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 06Aktionärsrenditen
| PRTK | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 2.3% | -1.7% | 0.8% |
| 1Y | -2.6% | 21.6% | 33.4% |
Rendite im Vergleich zur Industrie: PRTK underperformed the US Pharmaceuticals industry which returned 15.1% over the past year.
Rendite vs. Markt: PRTK underperformed the US Market which returned 13.8% over the past year.
Preisvolatilität
| PRTK volatility | |
|---|---|
| PRTK Average Weekly Movement | 1.6% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: PRTK has not had significant price volatility in the past 3 months.
Volatilität im Zeitverlauf: PRTK's weekly volatility has decreased from 13% to 2% over the past year.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1996 | 269 | Evan Loh | www.paratekpharma.com |
Paratek Pharmaceuticals, Inc.'s Grundlagenzusammenfassung
| PRTK grundlegende Statistiken | |
|---|---|
| Marktanteil | US$127.83m |
| Gewinn(TTM) | -US$62.73m |
| Umsatz(TTM) | US$177.00m |
0.7x
Kurs-Umsatz-Verhältnis-2.0x
Kurs-Gewinn-VerhältnisIst PRTK zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| PRTK Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$177.00m |
| Kosten der Einnahmen | US$64.13m |
| Bruttogewinn | US$112.87m |
| Sonstige Ausgaben | US$175.60m |
| Umsatz | -US$62.73m |
Zuletzt gemeldete Gewinne
Jun 30, 2023
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.09 |
| Bruttomarge | 63.77% |
| Nettogewinnspanne | -35.44% |
| Schulden/Eigenkapital-Verhältnis | -128.3% |
Wie hat sich PRTK auf lange Sicht entwickelt?
Historische Performance und Vergleiche